Seeing Is Believing
Currently out of the existing stock ratings of Chad Mabry, 32 are a BUY (96.97%), 1 are a HOLD (3.03%).
Analyst Chad Mabry, currently employed carries an average stock price target met ratio of 42.59% that have a potential upside of 17.05% achieved within 384 days. Previously, Chad Mabry worked at MLV.
Chad Mabry’s has documented 66 price targets and ratings displayed on 9 stocks. The coverage was on Energy, Healthcare sectors.
Most recent stock forecast was given on ALT, Altimmune at 07-Sep-2021.
Analyst best performing recommendations are on QEP (QEP RESOURCES).
The best stock recommendation documented was for QEP (QEP RESOURCES) at 7/21/2016. The price target of $19 was fulfilled within 25 days with a profit of $2.06 (12.16%) receiving and performance score of 4.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$38
$2.24 (6.26%)
$60
8 months 13 days ago
(26-Feb-2024)
0/9 (0%)
$7.17 (23.26%)
Hold
$32
$-3.76 (-10.51%)
$44
9 months 16 days ago
(23-Jan-2024)
1/10 (10%)
$0.42 (1.33%)
1
Buy
$45
$9.24 (25.84%)
$51
10 months ago
(08-Jan-2024)
7/22 (31.82%)
$10.47 (30.32%)
44
Hold
$40
$4.24 (11.86%)
$41
11 months 10 days ago
(29-Nov-2023)
1/4 (25%)
$8.43 (26.70%)
45
$40
$4.24 (11.86%)
$41
11 months 10 days ago
(29-Nov-2023)
5/14 (35.71%)
$8.43 (26.70%)
30
What Year was the first public recommendation made by Chad Mabry?